uniQure N.V. (NASDAQ:QURE - Get Free Report) insider Jeannette Potts sold 4,670 shares of uniQure stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $15.14, for a total value of $70,703.80. Following the sale, the insider now directly owns 115,073 shares of the company's stock, valued at $1,742,205.22. This trade represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
uniQure Price Performance
Shares of uniQure stock traded down $0.89 on Friday, reaching $14.21. The company's stock had a trading volume of 3,309,185 shares, compared to its average volume of 1,946,221. The company has a market capitalization of $778.42 million, a P/E ratio of -3.24 and a beta of 0.08. uniQure N.V. has a 52-week low of $3.73 and a 52-week high of $19.18. The stock has a 50-day moving average price of $14.09 and a 200-day moving average price of $13.79. The company has a quick ratio of 11.99, a current ratio of 11.99 and a debt-to-equity ratio of 1.53.
uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.25. The business had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. Analysts expect that uniQure N.V. will post -3.75 EPS for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on QURE shares. Chardan Capital reaffirmed a "buy" rating and set a $38.00 target price on shares of uniQure in a report on Friday, May 30th. Cantor Fitzgerald upgraded uniQure to a "strong-buy" rating in a research report on Monday, May 19th. Wall Street Zen cut uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. HC Wainwright reiterated a "buy" rating and set a $70.00 price target on shares of uniQure in a research report on Thursday, May 29th. Finally, Guggenheim reiterated a "buy" rating and set a $28.00 price target on shares of uniQure in a research report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $37.82.
Read Our Latest Report on QURE
Institutional Trading of uniQure
Several large investors have recently made changes to their positions in QURE. Oppenheimer & Co. Inc. purchased a new stake in shares of uniQure during the fourth quarter worth approximately $320,000. Raymond James Financial Inc. purchased a new stake in shares of uniQure during the fourth quarter worth approximately $1,951,000. Monaco Asset Management SAM purchased a new stake in uniQure in the 4th quarter valued at $2,414,000. Twin Tree Management LP purchased a new stake in uniQure in the 4th quarter valued at $77,000. Finally, JPMorgan Chase & Co. grew its holdings in uniQure by 14.7% in the 4th quarter. JPMorgan Chase & Co. now owns 453,784 shares of the biotechnology company's stock valued at $8,014,000 after buying an additional 58,246 shares in the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.
About uniQure
(
Get Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
